Joe Glass, PhD, MSW, is an associate investigator at Kaiser Permanente Washington Health Research Institute (KPWHRI). Before joining KPWHRI in July 2016, he was an assistant professor at the University of Wisconsin–Madison School of Social Work.
Dr. Glass’ research seeks to understand how effective health care interventions for unhealthy alcohol and drug use can reach more people. His research seeks to answer these questions:
Much of Dr. Glass’ recent work, funded by the National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and Kaiser Permanente, is studying approaches for routinely using smartphone and web-based treatments for unhealthy alcohol and drug use in health care. After receiving an MSW from the University of Michigan, Dr. Glass spent three years as a social worker at the Veterans Affairs Ann Arbor Healthcare System. As a licensed clinical social worker in a large mental health clinic, he developed expertise in social work case management and evidence-based treatments for anxiety, depression, and substance use disorders. Much of his research is driven by his clinical experiences, considering the many people struggling with both mental health difficulties and unhealthy substance use who have yet to receive addiction treatment.
Dr. Glass is an affiliate assistant professor of health services and of psychiatry and behavioral sciences, at the University of Washington.
Braciszewski JM, Idu AE, Yarborough BJH, Stumbo SP, Bobb JF, Bradley KA, Rossom RC, Murphy MT, Binswanger IA, Campbell CI, Glass JE, Matson TE, Lapham GT, Loree AM, Barbosa-Leiker C, Hatch MA, Tsui JI, Arnsten JH, Stotts A, Horigian V, Hutcheson R, Bart G, Saxon AJ, Thakral M, Ling Grant D, Pflugeisen CM, Usaga I, Madziwa LT, Silva A, Boudreau DM. Sex differences in comorbid mental and substance use disorders among primary care patients with opioid use disorder. Psychiatr Serv. 2022 Jun 16:appips202100665. doi: 10.1176/appi.ps.202100665. Online ahead of print. PubMed
Brown RT, Deyo B, Nicholas C, Baltes A, Hetzel S, Tilhou A, Quanbeck A, Glass J, O'Rourke A, Agarwal S. Screening in Trauma for Opioid Misuse Prevention (STOMP): results from a prospective cohort of victims of traumatic injury. Drug Alcohol Depend. 2022 Mar 1;232:109286. doi: 10.1016/j.drugalcdep.2022.109286. Epub 2022 Jan 21. PubMed
Williams EC, Chen JA, Frost MC, Rubinsky AD, Edmonds AT, Glass JE, Lehavot K, Matson TE, Wheat CL, Coggeshall S, Blosnich JR. Receipt of evidence-based alcohol-related care in a national sample of transgender patients with unhealthy alcohol use: Overall and relative to non-transgender patients. J Subst Abuse Treat. 2021 Jul 8:108565. doi: 10.1016/j.jsat.2021.108565 [Epub ahead of print] PubMed
Bagley SM, Chavez L, Braciszewski JM, Akolsile M, Boudreau DM, Lapham G, Campbell CI, Bart G, Yarborough BJH, Samet JH, Saxon AJ, Rossom RC, Binswanger IA, Murphy MT, Glass JE, Bradley KA. Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems. Addict Sci Clin Pract. 2021;16(1):46. doi: 10.1186/s13722-021-00249-3. PubMed
Glass JE, Matson TE, Lim C, Hartzler AL, Kimbel K, Lee AK, Beatty T, Parrish R, Caldeiro RM, Garza McWethy A, Curran GM, Bradley KA. Approaches for implementing app-based digital treatments for drug use disorders into primary care: a qualitative, user-centered design study of patient perspectives. J Med Internet Res. 2021;23(7):e25866. doi: 10.2196/25866. PubMed
Amy Lee describes how the LHS Program is helping KP Washington track and improve treatment for opioid use disorder.
Drs. Lapham and Bradley find frequency of cannabis use can be tied to other behavioral health patterns and needs.
Health Affairs blog, Mar 11, 2020